131 related articles for article (PubMed ID: 2598405)
1. Protection against cisplatin nephrotoxicity by prochlorperazine.
Kramer RA
Cancer Chemother Pharmacol; 1989; 25(3):156-60. PubMed ID: 2598405
[TBL] [Abstract][Full Text] [Related]
2. Drug interaction effects on antitumor drugs. XIII. Amelioration of cisplatin lethality and renal toxicity by chlorpromazine in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Biol Pharm Bull; 1993 Nov; 16(11):1104-7. PubMed ID: 8312864
[TBL] [Abstract][Full Text] [Related]
3. Effects of a cisplatin-chondroitin sulfate A complex in reducing the nephrotoxicity of cisplatin.
Zhang JS; Imai T; Otagiri M
Arch Toxicol; 2000 Aug; 74(6):300-7. PubMed ID: 11005675
[TBL] [Abstract][Full Text] [Related]
4. Amelioration of cisplatin-induced nephrotoxicity by the diuretic acetazolamide in F344 rats.
Osman NM; Copley MP; Litterst CL
Cancer Treat Rep; 1984; 68(7-8):999-1004. PubMed ID: 6540145
[TBL] [Abstract][Full Text] [Related]
5. Cisplatin-induced loss of kidney copper and nephrotoxicity is ameliorated by single dose diethyldithiocarbamate, but not mesna.
DeWoskin RS; Riviere JE
Toxicol Appl Pharmacol; 1992 Feb; 112(2):182-9. PubMed ID: 1311464
[TBL] [Abstract][Full Text] [Related]
6. Quantitative relationship between pharmacokinetics of unchanged cisplatin and nephrotoxicity in rats: importance of area under the concentration-time curve (AUC) as the major toxicodynamic determinant in vivo.
Nagai N; Ogata H
Cancer Chemother Pharmacol; 1997; 40(1):11-8. PubMed ID: 9137523
[TBL] [Abstract][Full Text] [Related]
7. Drug interaction effects on antitumour drugs (X): exacerbation of cisplatin lethality by bacterial lipopolysaccharide in mice.
Ishikawa M; Takayanagi Y; Sasaki K
Pharmacol Toxicol; 1991 May; 68(5):366-70. PubMed ID: 1946182
[TBL] [Abstract][Full Text] [Related]
8. Antitumor effects of three platinum complexes, (-)-(R)-2-aminomethylpyrrolidine(1,1-cyclobutanedicarboxylato)-platinum (II) monohydrate (DWA2114R), cis-diammine-(1,1-cyclobutanedicarboxylato)platinum(II) (CBDCA) and cis-diamminedichloroplatinum(II) (CDDP), in mice.
Endo K; Akamatsu K; Matsumoto T; Morikawa K; Koizumi M; Mitsui H; Koizumi K
Anticancer Res; 1992; 12(1):49-58. PubMed ID: 1567181
[TBL] [Abstract][Full Text] [Related]
9. L-methionine antagonism of cis-platinum nephrotoxicity.
Basinger MA; Jones MM; Holscher MA
Toxicol Appl Pharmacol; 1990 Mar; 103(1):1-15. PubMed ID: 2315922
[TBL] [Abstract][Full Text] [Related]
10. Protection effects of Taurine supplementation against cisplatin-induced nephrotoxicity in rats.
Saad SY; Al-Rikabi AC
Chemotherapy; 2002 Mar; 48(1):42-8. PubMed ID: 11901256
[TBL] [Abstract][Full Text] [Related]
11. Effects of disopyramide and verapamil on renal disposition and nephrotoxicity of cisplatin in rats.
Hanada K; Odaka K; Kudo A; Ogata H
Pharm Res; 1999 Oct; 16(10):1589-95. PubMed ID: 10554102
[TBL] [Abstract][Full Text] [Related]
12. Effects of sodium thiosulfate on the pharmacokinetics of unchanged cisplatin and on the distribution of platinum species in rat kidney: protective mechanism against cisplatin nephrotoxicity.
Nagai N; Hotta K; Yamamura H; Ogata H
Cancer Chemother Pharmacol; 1995; 36(5):404-10. PubMed ID: 7634382
[TBL] [Abstract][Full Text] [Related]
13. Para-aminobenzoic acid suppression of cis-diamminedichloroplatinum(II) nephrotoxicity.
Esposito M; Vannozzi MO; Viale M; Fulco RA; Collecchi P; Merlo F; De Cian F; Zicca A; Cadoni A; Poirier MC
Carcinogenesis; 1993 Dec; 14(12):2595-9. PubMed ID: 8269632
[TBL] [Abstract][Full Text] [Related]
14. The antitumour effect and toxicity of cis-platinum and N-methylformamide in combination.
Harpur ES; Langdon SP; Fathalla SA; Ishmael J
Cancer Chemother Pharmacol; 1986; 16(2):139-47. PubMed ID: 3948299
[TBL] [Abstract][Full Text] [Related]
15. Thioether suppression of cisplatin nephrotoxicity in the rat.
Jones MM; Basinger MA; Holscher MA
Anticancer Res; 1991; 11(1):449-53. PubMed ID: 2018382
[TBL] [Abstract][Full Text] [Related]
16. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
17. Selective protection against cis-diamminedichloroplatinum(II)-induced toxicity in kidney, gut, and bone marrow by diethyldithiocarbamate.
Bodenner DL; Dedon PC; Keng PC; Katz JC; Borch RF
Cancer Res; 1986 Jun; 46(6):2751-5. PubMed ID: 3009000
[TBL] [Abstract][Full Text] [Related]
18. Effects of prochlorperazine on experimental nephrotoxicity.
Harrison SD; Cox JL; Giles RC
Cancer Chemother Pharmacol; 1982 Dec; 10(1):62-7. PubMed ID: 6218930
[TBL] [Abstract][Full Text] [Related]
19. Iron- and ascorbic acid-induced lipid peroxidation in renal microsomes isolated from rats treated with platinum compounds.
Hannemann J; Duwe J; Baumann K
Cancer Chemother Pharmacol; 1991; 28(6):427-33. PubMed ID: 1934247
[TBL] [Abstract][Full Text] [Related]
20. Renal circadian clock regulates the dosing-time dependency of cisplatin-induced nephrotoxicity in mice.
Oda M; Koyanagi S; Tsurudome Y; Kanemitsu T; Matsunaga N; Ohdo S
Mol Pharmacol; 2014 May; 85(5):715-22. PubMed ID: 24567546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
